Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Olga Sala-TorraJerald P Radich

Abstract

Increasing the upper age limit for recipients of hematopoietic stem cell transplantation (HCT) naturally has also increased the age of the corresponding related donor population. Because aging is a risk factor for malignancies, the risk of transferring preexisting malignant or premalignant hemopoietic clones in the process of HCT might be expected to increase as well. Anecdotal clinical cases of malignancies derived from donor cells in patients undergoing HCT have been published since 1971. In this article, we report 12 new cases that fit 2 different categories: (1) cases in which clones with characteristics of lymphohemopoietic malignancies were transferred from the donors to the recipients and (2) cases in which the malignant clone evolved from healthy donor cells once transplanted into the recipient. Donors in the first group were significantly older than donors in the second group. A more systematic examination of the prevalence and biology of donor malignancies would merit study.

References

Apr 19, 1979·The New England Journal of Medicine·T C GossettC R Taylor
Sep 5, 1991·The New England Journal of Medicine·P V BrowneS R McCann
Mar 15, 1986·Cancer Genetics and Cytogenetics·G PalkaG Torlontano
Jul 1, 1985·British Journal of Haematology·J L SmithA J Provisor
Mar 19, 1981·The New England Journal of Medicine·P E NewburgerR J O'Reilly
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y LiuG A Cortopassi
Jan 17, 2002·The New England Journal of Medicine·K D BergJ R Eshleman
Aug 15, 2002·Transplantation·H Myron KauffmanAllan M Roza
Aug 29, 2003·The New England Journal of Medicine·Frederic BaronYves Beguin

❮ Previous
Next ❯

Citations

Apr 19, 2007·Cell and Tissue Banking·Manish J Gandhi, D Michael Strong
Mar 20, 2010·Stem Cell Reviews and Reports·Sergey V AnisimovAna S Correia
Aug 21, 2009·International Journal of Hematology·Natsue IgarashiKeiichi Nemoto
Sep 8, 2006·Nature·David Dingli, Martin A Nowak
Aug 31, 2007·Leukemia·S Z PavleticUNKNOWN Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee
May 25, 2007·Stem Cells and Development·Kenneth D McMilin, Susmita Dasgupta
Feb 28, 2007·Leukemia & Lymphoma·Guillermo J Ruiz-ArgüellesJavier Garcés-Eisele
Nov 19, 2010·Expert Review of Hematology·André TichelliUNKNOWN Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Jul 11, 2007·Expert Review of Molecular Diagnostics·Richard Josephson
Apr 14, 2015·Current Opinion in Genetics & Development·Andrea Strakova, Elizabeth P Murchison
Mar 18, 2011·American Journal of Clinical Pathology·Olga Sala Torra, Keith R Loeb
Jul 27, 2010·Transfusion Medicine Reviews·Hung YangAnthony J Keller
Mar 3, 2009·Seminars in Radiation Oncology·Joel S Greenberger, Michael Epperly
Jan 3, 2013·Cytometry. Part B, Clinical Cytometry·Daniela S KrauseFrederic I Preffer
Sep 21, 2010·Cytometry. Part B, Clinical Cytometry·Neil E CaporasoTait Shanafelt
Jun 19, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matthew P TilsonAmy S Duffield
Oct 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel H Wiseman
Feb 26, 2016·Hematology·Guillermo J Ruiz-DelgadoGuillermo J Ruiz-Argüelles
Oct 28, 2016·PLoS Pathogens·Michael J Metzger, Stephen P Goff
Jan 9, 2017·Blood·Claudia Korn, Simón Méndez-Ferrer
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beth ChristianKristie A Blum
Feb 13, 2018·Leukemia & Lymphoma·Christina KarantanouDaniela S Krause
Nov 30, 2006·Blood·Catherine M Flynn, Dan S Kaufman
Dec 28, 2019·Pigment Cell & Melanoma Research·Jackson R RichardsShannon J Odelberg
Jun 25, 2020·British Journal of Haematology·Lucía Prieto-TorresSocorro M Rodríguez-Pinilla
May 7, 2013·Expert Opinion on Drug Discovery·Susan E CrawordOlga V Volpert
Oct 19, 2016·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Michael R LokenDenise A Wells
Feb 9, 2017·International Journal of Hematology·Li-Li MuDeng-Li Hong
Jul 28, 2018·Leukemia·Nicole EngelUNKNOWN Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.